Linezolid for the Treatment of Multidrug‐Resistant, Gram‐Positive Infections: Experience from a Compassionate‐Use Program
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Linezolid was provided for treatment of multidrug-resistant, gram-positive infections through a compassionate-use program. Patients (n=796) received 600 mg of linezolid intravenously or orally every 12 h (828 treatment courses). Bacteremia was present in 46% of infections, endocarditis was present in 10.6%, and line-related infections were present in 31.1%. Other infections included intraabdominal infections (15.1%), complicated skin and skin-structure infections (13.3%), and osteomyelitis (10.7%). Causative pathogens included vancomycin-resistant enterococci (66.3%) and methicillin-resistant staphylococci (22.1%). Clinical intent-to-treat (ITT) outcomes in the evaluable population were as follows: cure, 73.3%; failure, 6.8%; and indeterminate, 19.9%. Microbiological ITT outcomes in evaluable patients were as follows: cure, 82.4%; failure, 14.1%; and indeterminate, 3.5%. At the test of cure assessment, the clinical cure and microbiological success rates were 91.5% and 85.8%, respectively. The most common adverse events possibly related to linezolid use were gastrointestinal disturbances (9.8% of cases), thrombocytopenia (7.4% of cases), decreased hemoglobin/hematocrit levels (4.1% of cases), and cutaneous reactions (4.0% of cases). Linezolid provided high rates of clinical cure and microbiological success in this complicated patient population, with very good overall tolerance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Birmingham et al 202 reported cure in 17 of 22 courses of therapy (77%) for E faecium IE.”
Citations
Cites
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Linezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K., & Quinn, J. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04376-2 · Cited by 542
Stevens, D. L., Herr, D., Lampiris, H., Hunt, J. L., Batts, D. H., Hafkin, B., & the Linezolid MRSA Study Group (2002) · Clinical Infectious Diseases · doi:10.1086/340353 · Cited by 506
Self-citationIn vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
Hematologic Effects of Linezolid: Summary of Clinical Experience
Gerson, S. L., Kaplan, S. L., Bruss, J. B., Le, V., Arellano, F. M., Hafkin, B., & Kuter, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2723-2726.2002 · Cited by 443
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions
Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H., Melchior, E. P., Swaney, S. M., Dunyak, D. S., Demyan, W. F., & Buysse, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2132 · Cited by 384
Vancomycin Resistance in Staphylococci
Srinivasan, A., Dick, J. D., & Perl, T. M. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.3.430-438.2002 · Cited by 285
Thrombocytopenia Associated with Linezolid Therapy
Attassi, K., Hershberger, E., Alam, R., & Zervos, M. J. (2002) · Clinical Infectious Diseases · doi:10.1086/338403 · Cited by 259
Slatter, J. G., Stalker, D. J., Feenstra, K. L., Welshman, I. R., BRUSS, J. B., Sams, J. P., Johnson, M. G., Sanders, P., Hauer, M. J., Fagerness, P. E., et al. (2001) · PubMed · Cited by 248
Research works printed but not linked: 8
- 2002, MMWR Morb Mortal Wkly Rep, 51, 565
- Stalker DJ, 1997, DC: American Society for Microbiology, 23
- Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days [abstract A115]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:23.
- Wynalda MA, 2000, Drug Metab Dispos, 28, 1014
- Slatter JG, 2001, Drug Metab Dispos, 29, 1136
- Dresser LD, Birmingham MC, Karchmer AW, Rayner CR, Falvin SM, Schentag JJ. Results of treating infective endocarditis with linezolid [abstract 2239]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:5.
- Zurenko GE, Todd WM, Hafkin B, etal Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1997:118.
- Forrest A, Rayner CR, Meagher AK, Birmingham MC, Schentag JJ. Pharmacostatistical modelling of hematologic effects of linezolid (L) in seriously-ill patients (pts) [abstract 283]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:5.
Cited by
Items 101–200 of 428
Dilley, M., & Geng, B. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08878-x · Cited by 66
Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?
Mave, V., Garcia-Diaz, J., Islam, T., & Hasbun, R. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp154 · Cited by 65
Vancomycin-Resistant Enterococci
Rubinstein, E., & Keynan, Y. (2013) · Critical Care Clinics · doi:10.1016/j.ccc.2013.06.006 · Cited by 73
Legout, L., Valette, M., Dezèque, H., Nguyen, S., Lemaire, X., Loïez, C., Caillaux, M., Beltrand, E., Dubreuil, L. J., Yazdanpanah, Y., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq281 · Cited by 63
Boak, L. M., Li, J., Rayner, C. R., & Nation, R. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01194-06 · Cited by 68
Self-citationCojutti, P. G., Merelli, M., Bassetti, M., & Pea, F. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz374 · Cited by 62
RAAD, I. I. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh144 · Cited by 62
Treatment of Resistant Enterococcal Urinary Tract Infections
Swaminathan, S., & Alangaden, G. J. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0138-8 · Cited by 68
Role of oral antimicrobial therapy in the management of osteomyelitis
Shuford, J. A., & Steckelberg, J. M. (2003) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200312000-00001 · Cited by 59
Recent advances in the treatment of infections due to resistant Staphylococcus aureus
Anstead, G. M., & Owens, A. D. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200412000-00007 · Cited by 57
Neurological and Psychiatric Adverse Effects of Antimicrobials
Bangert, M. K., & Hasbun, R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00649-9 · Cited by 58
Lundstrom, T. S., & Sobel, J. D. (2004) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2004.04.014 · Cited by 60
Therapeutic options for infections due to vancomycin-resistant enterococci
Wang, J., & Hsueh, P. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902811811 · Cited by 56
RAAD, I. I., Hanna, H. A., Hachem, R. Y., Dvorak, T. L., Arbuckle, R. B., Chaiban, G., & Rice, L. B. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3583-3585.2004 · Cited by 55
Enterococcal Endocarditis Revisited
Pericàs, J. M., Zboromyrska, Y., Cervera, C., Castañeda, X., Almela, M., García-de-la-Mària, C., Mestres, C. A., Falces, C., Quintana, E., Ninot, S. P. I., et al. (2015) · Future Microbiology · doi:10.2217/fmb.15.46 · Cited by 60
MANAGEMENT OF ACUTE HEMATOGENOUS OSTEOMYELITIS IN CHILDREN
Darville, T. L., & Jacobs, R. F. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000115629.52543.d0 · Cited by 54
Vancomycin-Resistant Enterococcal Bacteremia Pharmacotherapy
Patel, R., & Gallagher, J. C. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014556879 · Cited by 58
Linezolid for the treatment of complicated skin and skin structure infections in children
Yogev, R., Patterson, L. E. R., Kaplan, S. L., Adler, S. P., MORFIN, M. R., Martín, A., EDGE-PADBURY, B., NABERHUIS-STEHOUWER, S., & BRUSS, J. B. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000088671.35064.7c · Cited by 52
What’s New in the Treatment of Enterococcal Endocarditis?
Nigo, M., Munita, J. M., Arias, C. A., & Murray, B. E. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0431-z · Cited by 59
Tang, H.-J., Chen, C.-C., Zhang, C.-C., Su, B.-A., Li, C.-M., Weng, T., Chiang, S., Ko, W., & Chuang, Y.-C. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.07.012 · Cited by 52
Gallagher, J. C., Perez, M. E., Marino, E. A., LoCastro, L. G., Abrardo, L. A., & MacDougall, C. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.7.792 · Cited by 51
Antimicrobial resistance genes in bacteria from animal-based foods
Rodrigues, I. D. A., Ferrari, R. G., Panzenhagen, P., Mano, S. B., & Conte‐Júnior, C. A. (2020) · Advances in applied microbiology · doi:10.1016/bs.aambs.2020.03.001 · Cited by 51
Jones, R. N., Fritsche, T. R., Sader, H. S., & Ross, J. E. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.06.001 · Cited by 51
Nailor, M. D., & Sobel, J. D. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.010 · Cited by 54
Maclayton, D. O., & Hall, R. G. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h414 · Cited by 55
Enterococcal Endocarditis: Can We Win the War?
Munita, J. M., Arias, C. A., & Murray, B. E. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0270-8 · Cited by 54
Diemberger, I., Biffi, M., Martignani, C., & Boriani, G. (2011) · Expert Review of Medical Devices · doi:10.1586/erd.10.80 · Cited by 50
Treatment of Infections Due to Resistant Staphylococcus aureus
Anstead, G. M., Cadena, J., & Javeri, H. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-664-1_16 · Cited by 52
Minardi, M. L., Fato, I., Gennaro, F. D., Mosti, S., Mastrobattista, A., Cerva, C., Libertone, R., Saracino, A., Goletti, D., Girardi, E., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9071477 · Cited by 47
Strategies for managing today's infections
Carmeli, Y. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01957.x · Cited by 47
Community-Associated Methicillin-Resistant Staphylococcus aureus: New Bug, Old Drugs
Sabol, K., Echevarria, K. L., & Lewis, J. S. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g404 · Cited by 50
Das, D., Tulkens, P. M., Mehra, P., Fang, E., & Prokocimer, P. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit618 · Cited by 46
Faella, F. S., Pagliano, P., Fusco, U., Attanasio, V., & Conte, M. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01352.x · Cited by 45
Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections
Falagas, M. E., & Vardakas, K. Z. (2008) · Drug Safety · doi:10.2165/00002018-200831090-00004 · Cited by 46
Visual loss after silicone oil removal
Herbert, E. N., Liew, S. H. M., & Williamson, T. H. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.082610 · Cited by 44
Ang, J. Y., Lua, J. L., Turner, D. R., & Asmar, B. I. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000101784.83146.0c · Cited by 44
Current and prospective treatments for multidrug-resistant gram-positive infections
Rybak, J. M., Barber, K. E., & Rybak, M. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.820276 · Cited by 45
Boak, L. M., Li, J., Nation, R. L., & Rayner, C. R. (2005) · Biomedical Chromatography · doi:10.1002/bmc.597 · Cited by 43
Self-citationUpdate on the Use of Linezolid: A Pediatric Perspective
Tan, T. Q. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000142502.13252.20 · Cited by 43
Use of linezolid in pediatrics: a critical review
Dotis, J., Iosifidis, Ε., Ioannidou, M., & Roilides, E. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2009.10.002 · Cited by 42
Oehadian, A., Santoso, P., Menzies, D., & Ruslami, R. (2022) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2021.0122 · Cited by 49
Endocarditis Caused by Staphylococcus aureus with Reduced Susceptibility to Vancomycin
Woods, C. W., Cheng, A. C., Fowler, Jr., Moorefield, M., Frederick, J., Sakoulas, G., Meka, V. G., Tenover, F. C., Zwadyk, P., & Wilson, K. H. (2004) · Clinical Infectious Diseases · doi:10.1086/383027 · Cited by 42
Jian, Y., Lv, H., Liu, J., Huang, Q., Liu, Y., Liu, Q., & Li, M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00908 · Cited by 43
Elward, A. M., McAndrews, J. M., & Young, V. L. (2009) · Aesthetic Surgery Journal · doi:10.1016/j.asj.2009.01.010 · Cited by 44
Linezolid in the Treatment of Implant-related Chronic Osteomyelitis
Vercillo, M. T., Patzakis, M. J., Holtom, P. D., & Zalavras, C. G. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/blo.0b013e3180986d60 · Cited by 40
Linezolid induced toxic optic neuropathy
Kulkarni, K. N., & Priore, L. V. D. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.074237 · Cited by 40
Enterococcus faecalis Resistant to Linezolid: Case Series and Review of the Literature
Burleson, B. S., Ritchie, D. J., Micek, S. T., & Dunne, W. M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.13.1225.38086 · Cited by 40
Painful neuropathy with skin denervation after prolonged use of linezolid
Chao, C.-C., Sun, H.-Y., Chang, Y.-C., & Hsieh, S.-T. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.127910 · Cited by 39
Safety of Newer Parenteral Antibiotics
Stein, G. E. (2005) · Clinical Infectious Diseases · doi:10.1086/431671 · Cited by 39
Therapeutic options for vancomycin-resistant enterococcal bacteremia
Barber, K. E., King, S. T., Stover, K. R., & Pogue, J. M. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1001839 · Cited by 39
Joshi, L., Taylor, S. R. J., Large, O., Yacoub, S., & Lightman, S. (2009) · Clinical Infectious Diseases · doi:10.1086/597298 · Cited by 38
Tajima, M., Kato, Y., Matsumoto, J., Hirosawa, I., Suzuki, M., Takashio, Y., Yamamoto, M., Nishi, Y., & Yamada, H. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00427 · Cited by 38
Linezolid for the treatment of drug-resistant infections
Herrmann, D. J., Peppard, W., Ledeboer, N. A., Theesfeld, M., Weigelt, J. A., & Buechel, B. J. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.6.825 · Cited by 43
Linezolid: effectiveness and safety for approved and off-label indications
Vardakas, K. Z., Ntziora, F., & Falagas, M. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.14.2381 · Cited by 39
Vancomycin-Resistant Enterococcus Infections in Solid Organ Transplantation
Patel, G., & Snydman, D. R. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12099 · Cited by 39
Approaches to vancomycin-resistant enterococci
Torres‐Viera, C., & Dembry, L. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200412000-00006 · Cited by 37
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol
Aridoss, G., Amirthaganesan, S., & Jeong, Y. T. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.02.015 · Cited by 35
Polillo, M., Tascini, C., Lastella, M., Malacarne, P., Ciofi, L., Viaggi, B., Bocci, G., Menichetti, F., Danesi, R., Tacca, M. D., et al. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181d3f5cb · Cited by 34
Safety profiles of old and new antimicrobials for the treatment of MRSA infections
Bassetti, M., & Righi, E. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1142528 · Cited by 34
Ross, J. E., Fritsche, T. R., Sader, H. S., & Jones, R. N. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.09.025 · Cited by 34
Linezolid treatment of shunt-related cerebrospinal fluid infections in children: Clinical article
Yılmaz, A., Dalgıç, N., Müslüman, M., Sancar, M., Çolak, İ., & Aydın, Y. (2010) · Journal of Neurosurgery Pediatrics · doi:10.3171/2009.12.peds09421 · Cited by 34
SecA: A Potential Antimicrobial Target
Chaudhary, A. S., Chen, W., Jin, J., Tai, P. C., & Wang, B. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.42 · Cited by 35
Narayanan, N., Rai, R., Vaidya, P., Desai, A., Bhowmick, T., & Weinstein, M. P. (2019) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936119828964 · Cited by 34
Eliopoulos, G. M. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0055-1 · Cited by 33
Design, syntheses and evaluation of 4-oxo-5-cyano thiouracils as SecA inhibitors.
Chaudhary, A. S., Jin, J., Chen, W., Tai, P. C., & Wang, B. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.11.017 · Cited by 31
Schulte, D. M., Sethi, A. K., Gangnon, R. E., Duster, M. N., Maki, D. G., & Safdar, N. (2015) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-015-0089-9 · Cited by 31
Nguyen, A. V., Hoàng, L. H., Le, H. H. L., Sơn, N. T., Hong, L. T., Viet, T. T., Le, T. D., Ta, T. B., Vu, L. H., Nguyen, V. T. H., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s402278 · Cited by 31
Niwa, T., Watanabe, T., Suzuki, A., Ohmori, T., Tsuchiya, M., Suzuki, T., Ohta, H., Murakami, N., & Itoh, Y. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.01.012 · Cited by 31
Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome
Vardakas, K. Z., Kioumis, I. P., & Falagas, M. E. (2009) · Current Drug Metabolism · doi:10.2174/138920009787048446 · Cited by 31
Tammaro, L., Saturnino, C., DAniello, S., Vigliottá, G., & Vittoria, V. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.04.070 · Cited by 30
Update on the safety of linezolid
Metaxas, E. I., & Falagas, M. E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903049706 · Cited by 29
Qi, C., Zheng, X., Obias, A. A., Scheetz, M. H., Malczynski, M., & Warren, J. R. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.1098-1100.2006 · Cited by 29
Dagher, M. M., Fowler, V. G., Wright, P. W., & Staub, M. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa151 · Cited by 30
Westling, K., Julander, I., Ljungman, P. T., Jalal, S., Nord, C. E., & Wretlind, B. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.05.032 · Cited by 28
Cho, Y., Lim, H., Lee, S.-H., Cho, Y. L., Nam, H.-S., & Bae, K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00451-18 · Cited by 27
Maray, I., Rodríguez-Ferreras, A., Álvarez-Asteinza, C., Calero, M. A., Valledor, P., & Fernández, J. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.05.004 · Cited by 27
Early experience with linezolid for infections in orthopaedics
Harwood, P. J., Talbot, C., Dimoutsos, M., Sunderland, G., Shaw, D., Wilcox, M. H., & Giannoudis, P. V. (2006) · Injury · doi:10.1016/j.injury.2006.02.007 · Cited by 27
Harwood, P. J., & Giannoudis, P. V. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.405 · Cited by 27
Antimicrobial strategies for the prevention and treatment of cardiovascular infections
Furuya, E. Y., & Lowy, F. D. (2003) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.05.004 · Cited by 28
Ultrahigh resolution optical coherence tomography of birdshot retinochoroidopathy
Witkin, A. J., Duker, J. S., Ko, T. H., Fujimoto, J. G., & Schuman, J. S. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.076570 · Cited by 26
A Triad of Linezolid Toxicity: Hypoglycemia, Lactic Acidosis, and Acute Pancreatitis
Johnson, P. C., Vaduganathan, M., Phillips, K. M., & O’Donnell, W. J. (2015) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2015.11929310 · Cited by 26
Bradley, J. S., Flanagan, S. D., Arrieta, A. C., Jacobs, R. F., Capparelli, E. V., & Prokocimer, P. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001096 · Cited by 26
Update on the appropriate use of linezolid in clinical practice
Manfredi, R. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.4.455 · Cited by 32
Lima, L. S., de Brito, E. D. C. A., Mattos, K., Parisotto, E. B., Perdomo, R. T., & Weber, S. S. (2019) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2019.07.004 · Cited by 25
Empiric Treatment of Nosocomial Intra-Abdominal Infections: A Focus on the Carbapenems
Tellado, J. M., & Wilson, S. E. (2005) · Surgical Infections · doi:10.1089/sur.2005.6.329 · Cited by 29
Parissiadis, A., Dormoy, A., Fricker, D., Hanau, D., de la Salle, H., Cazenave, J.-P., Lenoble, P., & Donato, L. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.078097 · Cited by 25
Bell's Palsy Associated with Linezolid Therapy: Case Report and Review of Neuropathic Adverse Events
Thai, X. C., & Bruno‐Murtha, L. A. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.8.1183 · Cited by 27
Linezolid: In Infants and Children with Severe Gram-Positive Infections
Lyseng-Williamson, K. A., & Goa, K. L. (2003) · Pediatric Drugs · doi:10.2165/00128072-200305060-00009 · Cited by 25
New antibiotic agents for bloodstream infections
Vergidis, P. I., & Falagas, M. E. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.06.003 · Cited by 24
Novel pharmaceutical molecules against emerging resistant gram-positive cocci
Manfredi, R., & Sabbatani, S. (2010) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(10)70020-9 · Cited by 27
Youssef, S., Hachem, R. Y., Chemaly, R. F., Adachi, J. A., Ying, J., Rolston, K. V. I., & RAAD, I. I. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm506 · Cited by 24
Haddad, N., Ajaz, J., Mansour, L., Kasemodel, R., Jarvis, J., Jarad, J., Gorski, H., & Carr, M. (2023) · Antibiotics · doi:10.3390/antibiotics13010004 · Cited by 26
Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections
Grau, S., Ferrández, O., Urbina, O., Espona, M., Salas, E., & Ferrández, I. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s30728 · Cited by 27
Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections
Patanwala, A. E., Erstad, B. L., & Nix, D. E. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x162700 · Cited by 23
Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients
Ogami, C., Tsuji, Y., To, H., & Yamamoto, Y. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.05.025 · Cited by 23
Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci
Leone, S., Noviello, S., & Esposito, S. (2015) · Infection · doi:10.1007/s15010-015-0836-0 · Cited by 22
Sun, M., Hu, X.-R., Zhou, X., & Gu, J.-M. (2017) · Powder Diffraction · doi:10.1017/s0885715617000069 · Cited by 22
Chong, Y. P., Lee, S., Song, E. H., Lee, E. J., Jang, E.-Y., Kim, S., Choi, S., Kim, M., Jeong, J., Woo, J. H., et al. (2010) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365541003699623 · Cited by 24
Optometric referrals: towards a two way flow of information?
Evans, B. J. W., Harle, D. E., & Cocco, B. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.075531 · Cited by 22
Peripheral Neuropathy in an Adolescent Treated With Linezolid
Linam, W. M., Wesselkamper, K., & Gerber, M. A. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181945999 · Cited by 22
Metadata
- Authors
- Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Kalamazoo Public Library (US)
- Corresponding author
- Schentag, Jerome J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-01-15
- Volume
- 36
- Issue
- 2
- Pages
- 159-168
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2153039659
- Semantic Scholar
- 884899ebe7caae27908d4715f8dc57cf1db6c0c1
- Cited by
- 428
- References
- 25
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 7 · 2021: 9 · 2020: 18 · 2019: 12 · 2018: 17 · 2017: 14 · 2016: 13 · 2015: 21 · 2014: 19 · 2013: 19 · 2012: 13
- FWCI
- 21.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- linezolid, compassionate use program, vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, bacteremia, endocarditis, osteomyelitis, complicated skin and skin structure infections, intra-abdominal infection, clinical cure, adverse events, drug tolerability
- MeSH terms
- Linezolid, Acetamides, Adolescent, Adult, Aged, Anti-Infective Agents, Drug Interactions, Female, Humans, Male, Middle Aged, Treatment Outcome, Gram-Positive Bacterial Infections, Drug Resistance, Multiple, Oxazolidinones, Drug Resistance, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.